Baker Bros. Advisors (GP) LLC bought $28.8M of Kymera Therapeutics (KYMR)
Executed Jun 30 2025, disclosed Jun 30 2025, the same day.
Over the 21 trading sessions from the disclosed entry session (Jun 30 2025), the stock returned -2.1% (delay-adjusted); from the execution session (Jun 30 2025), -2.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Baker Bros. Advisors (GP) LLC (Director) filed 3 Form 4 reports as a reporting entity in the past 24 months (2 purchases, 1 sale), most often in BCYC. Across 2 priced purchase filings, the average 21-session return was -9.0% from execution and -6.6% from disclosure (delay-adjusted; derived). The largest single filing was $190.5M of ONC (732,827 sh across 2 lots, as filed), executed Feb 28 2025.
Healthcare · Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics th…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→